id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2018-D-1835-0010,FDA,FDA-2018-D-1835,Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,Other,Guidance,2019-11-18T05:00:00Z,2019,11,2019-11-18T05:00:00Z,,2024-11-12T23:12:40Z,,1,0,0900006484172150
FDA-2018-D-1835-0009,FDA,FDA-2018-D-1835,Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention; Guidance for Industry; Availability,Notice,Notice of Availability,2019-11-18T05:00:00Z,2019,11,2019-11-18T05:00:00Z,,2019-11-18T14:07:39Z,2019-24916,0,0,09000064841713b7
FDA-2018-D-1835-0002,FDA,FDA-2018-D-1835,Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,Other,Guidance,2018-07-11T04:00:00Z,2018,7,2018-07-11T04:00:00Z,2018-09-11T03:59:59Z,2024-11-07T01:34:05Z,,1,0,09000064834d0ab7
FDA-2018-D-1835-0001,FDA,FDA-2018-D-1835,"Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or
Prevention; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2018-07-11T04:00:00Z,2018,7,2018-07-11T04:00:00Z,2018-09-11T03:59:59Z,2018-09-08T01:04:03Z,2018-14749,0,0,09000064834d01dc